Merck, Dragonfly partner on trispecific antibodies for solid tumors

Cancer company Dragonfly Therapeutics Inc. (Waltham, Mass.) granted Merck & Co. Inc. (NYSE:MRK) an option to license exclusive, global rights to trispecific antibodies for solid tumors developed using Dragonfly's TriNKET technology platform.

Dragonfly is eligible to receive up to $695 million in upfront and milestone payments, plus royalties. Dragonfly declined to disclose details and Merck did not respond to inquiries. ...